Vascular endothelial growth factor 2
US5932540A · kind A · utility
77Cited by
4References
186Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 24, 1997 |
| Grant date | Aug 3, 1999 |
| Priority date | — |
| Expiry date | Dec 24, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.